|Publication number||US7329745 B2|
|Application number||US 10/864,818|
|Publication date||Feb 12, 2008|
|Filing date||Jun 10, 2004|
|Priority date||Jun 13, 2000|
|Also published as||US20050048050, US20080177047|
|Publication number||10864818, 864818, US 7329745 B2, US 7329745B2, US-B2-7329745, US7329745 B2, US7329745B2|
|Original Assignee||City Of Hope|
|Export Citation||BiBTeX, EndNote, RefMan|
|Non-Patent Citations (13), Referenced by (13), Classifications (15), Legal Events (5)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation-in-part of U.S. application Ser. No. 10/134,519, filed Apr. 30, 2002, now abandoned which is a continuation of U.S. application Ser. No. 09/609,776, filed Jul. 3, 2000, now abandoned which claims priority from provisional application No. 60/211,187, filed Jun. 13, 2000. Each of these applications are incorporated by reference into this application in its entirety.
The present invention is in the field of methods for treatment of hormone dependent cancers.
All references cited herein are incorporated by reference into this application in their entirety.
Insulin and Insulin-like Growth Factors stimulate the growth of human breast cancer cells in vitro. The Insulin-like Growth Factors I (IGF-I) and II (IGF-II) interact with cell surface receptors eliciting their cellular response. The IGF-I receptor (IGF-R) is the cell surface receptor for IGF-I having high binding affinity for this growth factor. However, IGF-R is also thought to have a high binding affinity for IGF-II. Interaction of either of these two growth factors to the IGF-R elicits intracellular responses through protein tyrosine phosphorylations, which can be blocked through the inhibition of the interaction of either IGF-I or IGF-II to the receptor.
These intracellular responses of IGF-IR signaling are implicated in the inducement of cell growth, proliferation and anti-apoptosis. It has been shown that the IGF-IR can not only induce normal cell growth but also induces tumor cell growth in both breast cancer and prostate cancer. In addition, the anti-apoptotic activity of IGF-IR protects cancerous tumor cells from chemotherapeutic treatments in breast cancers.
Therefore, a need exists for a method of inhibiting IGF-IR in order to inhibit tumor cell growth and increase sensitivity to chemotherapeutic agents. The activity of the IGF-IR can be inhibited by various methods. One of these methods comprises inhibiting the activation of the IGF-IR by preventing binding of agonist such as IGF-I or IGF-II. This can be achieved by blocking the IGF-IR binding site with antagonists.
Antibodies can be effective antagonists in inhibiting the interaction of the IGF-IR with IGF-I or IGF-II. αIR-3 (Arteaga, C. L. and Osborne, C. K.; Cancer Research 49, 6237-6241, 1989) is an antibody with high affinity for the IGF-IR and has been found to inhibit the interaction of IGF-I with the IGF-IR. In in vitro experimentation this murine antibody has been found to inhibit the growth of various tumor cells from breast cancer cell lines. In various tumor cells (MCF-7, MDA-231, ZR75-1, and HS578T) this αIR-3 could inhibit the IGF-I mediated DNA synthesis in vitro. However, in estrogen dependent tumor cells, such as MCF-7, ZR75-1 and T47D, the inhibition with αIR-3 of the IGF-IR in vivo failed to block estrogen stimulated DNA synthesis or proliferation. In contrast, in T61 tumor cells the αIR-3 antibody could inhibit tumor cell growth in vivo when used in combination with down-regulation of IGF-II synthesis by simultaneous treatment with estradiol and tamoxifen. It appears that αIR-3 is a better antagonist for IGF-I blockage compared to its ability to inhibit interaction of IGF-II with IGF-IR.
Another murine antibody against the α-subunit of IGF-IR, 1H7 (Li S. et al; Biochemical and Biophysical Research Communications, 196, 92-98, 1993), has shown good results in inhibiting the activation of IGF-IR. In in vitro experimentation with NIH3T3 cells over-expressing human IGF-IR the 1H7 antibody inhibits basal, IGF-I or IGF-II stimulated DNA synthesis. A second antibody raised against the IGF-IR α-subunit, 2C8, however, is unable to block IGF-IR activation by either IGF-I or IGF-II while having binding affinities for the receptor.
While these two murine antibodies, αIR-3 and 1H7, have shown results in inactivation of the IGF-IR in vitro, their ability to inhibit estrogen dependent tumor cell growth in vivo is limited. Furthermore, the monoclonal murine antibodies have their obvious disadvantages in their use for human treatment or other mammals. In addition, their relative complexity limits the ability to manipulate the antibodies to optimize their use in the treatment of mammalian hormone dependent cancers. Accordingly, improvements are sought.
In accordance with the present invention, a method of inhibiting the growth of hormone dependent tumor cells in a mammal comprises administering to said mammal an anti insulin-like growth factor I receptor (IGF-IR) recombinant antibody. In a preferred embodiment, the method comprises administering a single chain antibody (scFv). In a further preferred embodiment the method comprises administering a chimeric single chain antibody in which a constant domain has been linked to the single chain antibody.
There also is provided a novel IGF-IR antagonist comprising a recombinant antibody which blocks agonist interaction with the IGF-IR. The antibody comprises antigen binding portions that have the specificity of the antigen binding sites of the murine 1H7 antibody. The recombinant antibody can be a single chain or double chain antibody. In one embodiment of the invention, the antibody is in the form of a novel chimeric single-chain antibody against IGF-IR.
In a preferred embodiment of the invention, the antibody is in the form of the single chain recombinant antibody of SEQ ID NO:1.
The present invention provides a method of inhibiting hormone dependent tumor growth by blocking the activation of the Insulin-like Growth Factor I receptor (IGF-IR). This blockage can be accomplished by exposing hormone dependent tumor cells to an antagonist of IGF-IR. Inhibition of IGF-IR can lead to a decrease in cell growth and can also render the hormone dependent tumor cells more susceptible to therapeutic agents. Alternatively, the antagonist interaction with IGF-IR, inhibiting the activation of the receptor, can lead to apoptosis of the hormone dependent tumor cells.
Therefore, the invention provides a method of treatment of mammals suffering from hormone dependent tumor cell growth by administering to the mammal an anti-IGF-IR recombinant antibody. Preferably the invention provides for a treatment of mammals suffering from estrogen dependent cancer, such as breast cancer. In addition, the treatment comprises administering to said mammal an anti-IGF-IR recombinant antibody in combination with one or more therapeutic agents, such as tamoxifen, which are effective in reducing the growth of hormone-dependent tumors.
In a preferred embodiment of the invention the anti-IGF-IR antibody is a recombinant antibody wherein the antigen binding portions of the antibody are comparable to the antigen binding portions of murine antibody 1H7. Comparable antigen binding portions are ones in which the amino acid sequences have the binding specificity of the amino acid sequence of the antigen binding portions of the murine antibody 1H7. The CDRs within the binding portion have at least 90% identity to the corresponding CDR of 1H7, preferably 95% identity and most preferably full identity. Particularly preferred is a single chain recombinant antibody, such as the αIGF-IR scFv or αIGF-IR scFv-Fc antibody comprising antigen binding portions comparable to the antigen binding portions of murine antibody 1H7, or even more preferred is the single chain recombinant antibody of SEQ ID NO:1. The single chain antibodies are advantageous because of the relative ease in their expression, purification and manipulation. The expression of such antibodies in expression systems makes them more susceptible to large scale production and purification. In addition, manipulation of such single chain antibodies may consist of altering such antibodies to covalently attach other therapeutic agents. Such agents can, for example, include toxins, enzymes, or radionucleotides. The recombinant single chain antibody conjugated with such agents can block IGF-IR induced tumor cell growth and target such agents to said tumor cells which have been made more susceptible to apoptosis by the inhibition of IGF-IR.
The single chain antibody comprises at least an Fv domain capable of blocking IGF-IR interaction with IGF-I or IGF-II. The IGF-IR scFv comprises both the antigen binding region of a light chain variable domain, VL, and the antigen binding region of a heavy chain variable domain, VH, coupled by a short linker peptide. In a preferred embodiment, the VL domain and the VH domain are derived from the 1H7 antibody against the α-subunit of IGF-IR. The IGF-IR scFv can be tagged with a short peptide such as the FLAG epitope to facilitate purification of the soluble IGF-IR scFv from the medium of the expression system. The DNA coding for the VL and VH domains are obtainable by sequencing said domains from a parental antibody, in a preferred embodiment said parental antibody being 1H7. A recombinant DNA then can be constructed comprising, in order, coding sequences for the N-terminal signal peptide, the antigen binding region of the VL domain, a linker peptide, the antigen binding region of the VH domain and a C-terminal tag peptide for purification and identification. Said genetically engineered antibody can be expressed in myeloma or bacterial cell expression systems. The monovalent recombinant single chain antibody IGF-IR scFv can be purified from the medium of said expression system by conventional protein purification methods, such as, for example, affinity chromatography.
The linker peptide is chosen based upon known structural and conformational information of peptide segments and is selected so that it will not interfere with the tertiary structure of the single chain antibody and its uses. Typically, a linker of between about 6 and 50 amino acids is preferred for ease and economics of preparation.
One such single chain recombinant antibody comprising antigen binding portions comparable to the antigen binding portions of murine antibody 1H7 is the peptide with the binding specificity of the sequence shown in SEQ ID NO:1 shown in
GGGGSGGGSGGGGSGGGS. (SEQ ID NO: 5)
Each of these domains (VL and VH) contain three complimentarity determining regions (CDRs) responsible for antigen recognition. The three CDRs of the VL domain KASQDVNTA (SEQ ID NO:6), WASTRMMT (SEQ ID NO:7), and HQHYTTPYT (SEQ ID NO:8), are designated CDR1L, CDR2L and CDR3L respectively. The three CDRs of the VH domain, IYAMS (SEQ ID NO:9), SISNGGTTYYPDSVKG (SEQ ID NO:10), and TFYYSFPRAMDY (SEQ ID NO:11) are designated CDR1H, CDR2H, and CDR3H respectively.
In one embodiment of the invention the soluble IGF-IR scFv is a chimeric antibody which further comprises an Fc domain. In this embodiment, the recombinant DNA will comprise the coding sequence of IGF-IR scFv minus the C-terminal tag peptide, coupled to a coding sequence for an Fc domain. Desirably, the Fc domain comprises the CH2 and CH3 regions of an antibody heavy chain constant domain. The recombinant DNA can be expressed in a myeloma or bacterial expression system in accordance with conventional techniques and said single-chain antibody IGF-IR scFv-Fc can be purified using conventional protein purification methods. The IGF-IR scFv-Fc exists preferably in its divalent form. The IGF-IR scFv-Fc can comprise a humanized form of the IGF-IR scFv, such as, for example, by using a coding sequence of a human Fc domain when constructing the recombinant DNA. Said single chain antibodies (IGF-IR scFv or IGF-IR scFv-Fc) subsequently can be modified, if desired, and attached to other therapeutic agents.
To treat mammals suffering from hormone dependent cancer, preferably from estrogen dependent breast cancer, the recombinant single-chain antibodies (IGF-IR scFv or IGF-IR scFv-Fc) can be administered in a pharmaceutically acceptable composition as the sole therapeutic or in combination with one or more other therapeutic agents, such as tamoxifen, which are effective in reducing hormone-dependent tumor cell growth. The tamoxifen or other therapeutic agent can be administered in accordance with conventional therapeutic methods, such as parenteral or subcutaneous administration. Administration of said recombinant single chain antibodies can be used as a method of inhibiting tumor cell growth in vivo or to induce susceptibility of said tumor cells to therapeutic agents.
In light of the preceding description, one skilled in the art can use the present invention to its fullest extent. The following examples, therefore, are to be construed as illustrative only and not limiting in relation to the remainder of the disclosure.
Cloning of 1H7 Variable Domains by RT-PCR.
Heavy and light chains of mouse monoclonal antibody 1H7 (Li, S. et al; Biochemical and Biophysical Research Communications, 196, 92-98, 1993) were separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE; 12.5% polyacrylamide gel), under reducing conditions, blotted onto a polyvinylidene difluoride membrane, and subjected to N-terminal amino acid sequence determination by Edman degradation. Degenerate oligonucleotides, used as upstream primers, were synthesized on the N-terminal sequences of the heavy and light chains of 1H7 while the constant region oligonucleotides for the downstream primers were designed and synthesized according to the published nucleotide sequences. Primers (Table 1) containing the EcoRI site were used to amplify the heavy- and light-chain variable regions (VH and VL, respectively) from 1H7 poly(A) rich mRNA by reverse transcriptase polymerase chain reaction (RT-PCR). PCR products were ligated into the EcoRI site of pBleuscriptII SK. Escheria coli XL1-Blue was transformed with the vectors encoding PCR-generated VH and VL sequences.
The N-terminal amino acid sequences of the heavy-and light-chains of 1H7 were determined to be EVKVVESGGGLVKPG (SEQ ID: NO 12) and DIVMTQSHKFMSTSV (SEQ ID: NO: 13) respectively.
Primers for PCR amplification of variable
regions of heavy and light chains of 1H7
1 2 3 4 5 6
Asp Ile Val Met Thr Gln
[SEQ IN NO: 14]
gggaattc GAC ATT GTG ATG ACC CAA 3′
[SEQ IN NO: 15]
T C C A G
C-region amino acid
Ser Ile Phe Pro Pro Ser
[SEQ IN NO: 16]
5′ TCC ATC TTC CCA CCA TCC gaattccg 3′
[SEQ IN NO: 17]
1 2 3 4 5 6
Glu Val Lys Val Val Glu
[SEQ IN NO: 18]
gggaattc GAA GTA AAA GTA GTA GAA 3′
[SEQ IN NO: 19]
G C G C C G
G G G
C-region amino acid
Val Tyr Pro Leu Ala Pro
[SEQ IN NO: 20]
5′ GTC TAT CCA CTG GCC CCT gaattccg 3′
[SEQ IN NO: 21]
Design of αIGF-IR Antibodies.
Two soluble forms of 1H7-based αIGF-IR antibodies, scFv and scFv-Fc, were designed as schematically presented in
The gene encoding the αIGF-IR scFv was constructed using the N-terminal signal peptide derived from the mT84.66 light chain, VL DNA, an oligonucleotide encoding the linker peptide (GGGGSGGGS)2 (SEQ ID NO: 5), VH DNA, and a C-terminal tag (including DYKD; SEQ ID NO: 22]), and assembled using splice-overlap extension PCR. The resulting DNA encoding αIGF-IR scFv is shown in
To construct the gene encoding αIGF-IR scFv-Fc, a SalI fragment containing the human IgG1 Fc (cDNA clone from Dr. J. Schlom, Laboratory of Tumor Immunology and Biology, division of Cancer Biology and Diagnosis, NCI, Bethesda, Md.) was inserted into the unique XhoI site of pcDNA/αIGF-IR scFv. The HindIII fragment encoding αIGF-IR scFv-Fc, isolated from the pcDNA/αIGF-IR scFv-Fc plasmid, was inserted into the HindIII site of pEE12-1. This plasmid encodes a glutamine synthase gene that provides a selection system for myeloma NS0 cells in L-glutamine-deficient selection medium.
Cell Culture, Transfection and Purification of αIGF-IR scFv or αIGF-IR scFv-Fc.
Murine myeloma Sp2/0 cells were transfected with pcDNA/αIGF-IR scFv by electroporation, and incubated at 37° C. for 3 days in a humidified 5% CO2 atmosphere. On day 4, cells were collected, counted and placed in 24-well plates (105 cells/well) in regular medium containing 400 μg/ml G418. Murine myeloma NS0 cells were grown in selective medium consisting of L-glutamine-free Celltech DME (JRH Biosciences, Lenexa, Kans.), dialyzed fetal calf serum (Gibco/BRL, Gaithersburg, Md.), and glutaminase synthase supplement (JRH Biosciences, Lenexa, Kans.). Murine myeloma NS0 cells were stably transfected with pEE12-1/αIGF-IR scFv-Fc by electroporation and transferred to non-selective culture medium in a 96-well plate (50 μl/well), and incubated overnight. The next day 150 μl of selection medium was added to each well, and the cells were incubated for three weeks until discrete surviving colonies appeared.
To purify αIGF-IR scFv by affinity chromatography, 150 ml of conditioned medium (CM), collected from Sp2/0 cells, were applied to 6 ml αFLAG M2 mAb (Eastman Kodak Co., Rochester, N.Y.) conjugated to Sepharose 4B (0.2 mg/ml gel), and αIGF-IR scFv-Fc was eluted from the column with FLAG peptide. Eluates were concentrated and dialyzed, using an Ultrafree-4 spin column (Millipore, Bedford, Mass.). Based on the recovery of approximately 4 μg of αIGF-IR scFv protein from purifying 150 ml CM, the level of αIGF-IR scFv expression was estimated to be approximately 20 ng/ml CM.
To purify αIGF-IR scFv-Fc approximately 40 ml cell culture supernatants collected from αIGF-IR scFv-Fc expressing NS0 transfectants were adjusted to pH 8.0 by adding 1/20 volume 1.0M TRIS (pH 8.0), and passed through a protein-A-Sepharose CL 4B column. αIGF-IR scFv-Fc was eluted from the column with 100 mM glycine buffer pH 3.0, collected in 1.5 ml conical tubes containing 1/10 volume 1M TRIS (pH 8.0). The estimated expression level of αIGF-IR scFv-Fc in this expression system ranged between 45 μg/ml and 85 μg/ml.
Inhibition of Agonist Binding to Purified IGF-IR by 1H7 and αIGF-IR scFv-Fc.
The affinity constants of 1H7 (109 M−1) and αIGF-IR scFv-Fc (108 M−1) for IGF-IR were determined using a BIAcore instrument (BIAcore Inc., Piscataway, N.J.). Analytes, at various concentrations, were passed over IGF-IR-immobilized chips (0.3 μg/chip) at a flow rate of 5 μl/min.
The in vitro potency of inhibition of purified IGF-IR by αIGF-IR scFv-Fc for both IGF-I and IGF-II binding is seen in
Effect of αIGF-IR scFv-Fc on Cell Growth.
Using the MTT method the effect of extracellular addition of αIGF-IR scFv-Fc or 1H7 on cell growth was determined on NIH3T3 cells over expressing IGF-IR. Cell growth was significantly inhibited after four days of treatment with 10 nM or 100 nM 1H7 mAb, see
Effect of αIGF-IR scFv-Fc on Tumor Growth In vivo.
The human breast MCF-7 cell line was obtained from American Type Culture Collection (Rockville, Md.). MCF-7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum. Female athymic mice (BALB/C nude, Charles River Facility for NCI, Frederick, Md.), 4 weeks old, that had received 0.25 mg 17β-estradiol pellet one week previously were inoculated in the flank with 107 MCF-7 cells (day 0). On day 3, intraperitoneal or subcutaneous injections near the tumor sites of αIGF-IR scFv-Fc into each of three mice (500 μg/0.1 ml phosphate buffered saline, PBS/mouse, twice a week) was started, and continued for two weeks.
The recombinant single chain antibody αIGF-IR scFv-Fc inhibits MCF-7 tumor cell growth in athymic mice. As shown in
Effect of αIGF-IR scFv-Fc in Combination with Anti-Neoplastic Agent Doxorubicin (DOX) on Tumor Growth In vivo.
In combination with Doxorubicin (DOX), αIGF-IR scFv-Fc inhibits tumor cell growth, as shown in
Effect of αIGF-IR scFv-Fc in Combination with Anti-Estrogen Agent Tamoxifen (TAM) on Tumor Growth In vivo.
In combination with the anti-estrogen drug Tamoxifen (TAM), αIGF-IR scFv-Fc inhibits T61 tumor cell growth in vivo as is shown in
|1||Arteaga et al., "Growth Inhibition of Human Breast Cancer Cells in Vitro With an Antibody Against the Type I Somatomedin Receptor," Cancer Research, 49, 6237-6241, Nov. 15, 1989.|
|2||Bergers, G., et al., Extrinsic regulators of epithelial tumor progression: metalloproteinases, Current Opinion in Genetics & Development, vol. 10, 2000, pp. 120-127.|
|3||Brünner et al., "Effect of Endocrine Therapy on Growth of T61 Human Breast Cancer Xenografts is Directly Correlated to a Specific Down-regulation of Insulin-Like Growth Factor II (IGF-II)," Eur J Cancer, vol. 29A, No. 4, pp. 562-569, 1999.|
|4||Curti, B.D., Physical barriers to drug delivery in tumors, Critical Reviews in Hematology/Oncology, vol. 14, 1993, 29-39.|
|5||Ezeh, P.I. et al., Differential activation of ErbB receptors in the rat olfactory mucosa by transforming growth factor-alpha and epidermal growth factor in vivo, Journal of Neurology, vol. 37, No. 2, 1998, pp. 199-210.|
|6||Furlanetto et al., "Effects of Insulin-Like Growth Factor Receptor Inhibition on Human Melanomas in Culture and In Athymic Mice," Cancer Research, 53, 2522-2526, Jun. 1, 1993.|
|7||Gura, T., Systems for identifying drugs are often faulty, Science, vol. 278, 1997, pp. 1041-1042.|
|8||Jain, R.K., Barriers, to drug delivery in solid tumors, Scientific American, vol. 271, 1994, pp. 58-65.|
|9||Lewis, G.D., et al., Differential responses to human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cander Immunology Immunotherapy, vol. 37, No. 4, 1993, pp. 255-263.|
|10||Li et al., "Two New Monoclonal Antibodies Against the alpha Subunit of the Human Insulin-Like Growth Factor-I Receptor," Biochemical and Biophysical Research Communications, vol. 196, No. 1, Oct. 15, 1993, pp. 92-98.|
|11||Stancovski, I., et al., Mechanistic aspects of the opposing effects of monoclonal antibodies of the ERBB2 receptor in tumor growth, Proceedings of the National Academy of Sciences USA, vol. 88, 1991, pp. 8691-8695.|
|12||Strobel, T., et al., Beta 1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro, Gynecologic Oncology, vol. 73, No. 3, 1999, pp. 362-367.|
|13||Szollosi, J., et al., ERBB-2 (HER2/neu) gene copy No., p185-HER-2 overexpression, an intratumor heterogeneity in human breast cancer, Cancer Research, vol. 55, No. 22, 1994, pp. 5400-5407.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7638605||May 3, 2004||Dec 29, 2009||ImClone, LLC||Fully human antibodies directed against the human insulin-like growth factor-1 receptor|
|US7968093||Dec 17, 2009||Jun 28, 2011||Imclone Llc||Fully human antibodies directed against the human insulin-like growth factor-1 receptor|
|US7972600||Feb 5, 2007||Jul 5, 2011||Imclone Llc||IGF-IR antagonists as adjuvants for treatment of prostate cancer|
|US7982024||Jul 19, 2011||Amgen Fremont Inc.||Antibodies to insulin-like growth factor I receptor|
|US8128929||Jun 19, 2006||Mar 6, 2012||Imclone Llc||Antibodies against PDGFRa|
|US8425911||Oct 19, 2011||Apr 23, 2013||Imclone Llc||Methods of treating secondary bone tumors with antibodies against PDGFR alpha|
|US8574578||Oct 19, 2011||Nov 5, 2013||Imclone Llc||Antibodies against PDGFRα to inhibit tumor growth|
|US8642037||Jun 27, 2011||Feb 4, 2014||Amgen Fremont Inc.||Antibodies to insulin-like growth factor I receptor|
|US9234041||Dec 19, 2013||Jan 12, 2016||Pfizer Inc.||Antibodies to insulin-like growth factor I receptor|
|US20080025990 *||May 3, 2004||Jan 31, 2008||Ludwig Dale L||Fully Human Antibodies Directed Against the Human Insulin-Like Growth Factor-1 Receptor|
|US20090110678 *||Jun 19, 2006||Apr 30, 2009||Imclone Systems Incorporated||Receptor antagonists for treatment of metastatic bone cancer|
|US20090175868 *||Feb 5, 2007||Jul 9, 2009||Ludwig Dale L||IGF-IR antagonists as adjuvants for treatment of prostate cancer|
|US20100158920 *||Dec 17, 2009||Jun 24, 2010||Imclone Llc||Fully human antibodies directed against the human insulin-like growth factor-1 receptor|
|U.S. Classification||536/23.5, 530/388.22, 530/387.3|
|International Classification||C07H21/04, A61K39/395, C07K16/28|
|Cooperative Classification||C07K2317/24, A61K2039/505, C07K2317/73, A61K39/39541, C07K2317/622, C07K2319/00, C07K16/2863|
|European Classification||A61K39/395C1, C07K16/28G|
|Oct 29, 2004||AS||Assignment|
Owner name: CITY OF HOPE, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FUJITA-YAMAGUCHI, YOKO;REEL/FRAME:015315/0838
Effective date: 20040915
|Oct 23, 2008||AS||Assignment|
Owner name: US GOVERNMENT - SECRETARY FOR THE ARMY, MARYLAND
Free format text: CONFIRMATORY LICENSE;ASSIGNOR:CITY OF HOPE;REEL/FRAME:021719/0734
Effective date: 20081010
|Nov 18, 2008||CC||Certificate of correction|
|Aug 9, 2011||FPAY||Fee payment|
Year of fee payment: 4
|Aug 11, 2015||FPAY||Fee payment|
Year of fee payment: 8